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Abstract: 
In cardiovascular system, activation of Endothelin receptors causes vasoconstriction which leads to Pulmonary Arterial 
Hypertension (PAH). Endothelin receptor antagonism has emerged as an important therapeutic strategy in pulmonary arterial 
hypertension. Bosentan is intended to affect vasoconstriction, hypertrophic and fibrotic effects by blocking the actions of receptors 
ETA and ETB. In this study we identified the action of Bosentan on endothelin B receptor using docking studies with homology 
modeled endothelin B receptor. Through the modeled protein, the flexible Docking study was performed with Bosentan and its 
derivatives with theoretically predicted active sites. The results indicated that amino acid ARG82, ARG84 and HIS197 present in 
endothelin B receptor are core important for binding activities and these residues are having strong hydrogen bond interactions 
with Bosentan. We have investigated the Bosentan and its derivatives interactions and scoring parameters using gold docking 
package. Among the docked compounds, one of the Bosentan derivatives BD6 shows better interaction than Bosentan with 
endothelin B receptor. Our results may be helpful for further investigations in both in vivo and in vitro conditions. 
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Background: 
Pulmonary Arterial Hypertension (PAH) is a severe disease of 
Pulmonary arteries involving vasoconstriction, pulmonary 
vascular remodeling, and insitu thrombosis [1]. PAH develops 
the blood flow through the pulmonary arteries and the right 
s i d e  o f  t h e  h e a r t  i s  u n d e r  i n c r e a s i n g  s t r a i n  t o  p u m p  b l o o d  
through to the lungs, leads to breathlessness, chest stiffness and 
fatigue [2]. Laboratory and clinical investigations have clearly 
shown that Endothelin receptors are over expressed in several 
forms of pulmonary vascular disease and play a significant 
pathogenetic role in the development and progression of 
pulmonary vasculopathy [3]. There are two distinct receptors 
for the endothelin family of peptides, endothelin receptor A 
(ETA) and endothelin receptor B (ETB) and these two receptors 
have unique locations and binding affinities for the endothelin 
peptides [4]. The ETA receptors are expressed on pulmonary 
vascular smooth muscle cells, whereas ETB receptors are located 
on both pulmonary vascular endothelial cells and smooth BIOINFORMATION  open access 
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muscle cells. ETB receptors have an important role in the ET- 
dependent protracted presser effects. Under some 
circumstances it actually contributes to pulmonary 
vasoconstriction, through a population of ETB receptors located 
on vascular smooth muscle cells [5]. Bosentan is the first oral 
endothelin receptor antagonist (ERA) that blocks the effect of 
endothelin receptors. It belongs to a class of highly substituted 
pyrimidine derivatives, with no chiral centers. It is designated 
chemically as 4-tert-butyl-N - [6-(2-hydroxy-ethoxy) -5- (2-
methoxy-phenoxy) - [2, 2] - bipyrimidin-4-yl] - benzene 
sulfonamide monohydrate [6]. In vitro functional experiments 
performed on animal and human tissues showed that Bosentan 
behaves as a competitive antagonist on ET receptors. It is 
intended to inhibit vasoconstriction, hypertrophic and fibrotic 
effects by blocking the actions of receptors (ETA and ETB) which 
leads to reduction of blood pressure in lungs. Bosentan interact 
with the binding of ET-1 and other ET peptides to both ETA and 
ETB receptors [7]. The objective of this work is to identify the 
role the mechanism of Bosentan on ETB receptor and to model 
the protein, and to identify the interactions with Bosentan and 
their derivatives. 
 
Methodology: 
The sequence information of Endothelin-B receptor- 
Homosapiens  (Accession No: P24530) is retrieved from Swiss 
Prot (http://www.swissprot.org) and submitted to SBASE 
server (http:// hydra icgeb.trieste.it/sbase) for domain 
prediction. The predicted domain (118-386) is search for 
similarity (Protein blast) and the related protein structure was 
identified by the BLAST program against PDB. The 
macromolecular structure (PDB ID 3C9M [8]), which shows 
maximum identity with high score and less e-value designated 
as template. The 3D model was generated by using the 
academic version of MODELER9v7 
(http//:www.salilab.org/modeler), based on the information 
obtained from sequence alignment [9]. The 3D structure 
obtained from modeler were further refined through molecular 
dynamics and equilibration methods using NAMD 2.5 with 
CHARMM27 force field and the system contains TIP3P water 
model. The energy of the structure was minimized with 10,000 
steps with cutoff of 12 Å for vdW interactions. The equilibrated 
system was simulated with 1 picoseconds (PS); to hold back the 
original conformation, for that (NPT) constant pressure and 
310K constant temperatures has been choosed [10]. Finally, the 
structure having the least energy with low RMSD was used for 
further studies. The final structure obtained, was analyzed by 
Ramachandran's map drawn using PROCHECK v.3.0, and 
environment profile using ERRAT graph (Structure Evaluation 
server). The model satisfying all the parameters after evaluation 
was considered for the further process [9]. Theoretical Active 
site prediction of Endothelin-B receptor was predicted using 
CASTP server. CASTP identifies and measures pockets and 
pocket mouth openings, as well as cavities. Here we input the 
modeled protein for predicting the ligand binding sites and the 
CASTP server predicts the amino acids crucial for binding 
interactions [11]. The Bosentan library was generated manually 
by addition of polar groups in the required position and 30 new 
compounds were generated as derivatives of Bosentan Table 1 
(see supplementary material). The Docking interactions are 
d o n e  w i t h  G O L D  ( G e n e t i c  O p t i m i z a t i o n  o f  L i g a n d  D o c k in g ) ,  
based on genetic algorithm which is used for docking of 
Bosentan and their derivative compounds [12]. The interaction 
of these derivatives with the active site residues are thoroughly 
studied using molecular mechanics calculations. The 
parameters used for GA were population size 100, selection 
pressure 1.1, and operator parameters for crossover, mutation 
and migration were set to 100, 100 and 10 respectively. Default 
cutoff values of 3.0 X (dH-X) for hydrogen bonds and 6.0 X for 
vdW were employed. During docking, the default algorithm 
speed was selected and the ligand binding site in the 
Endothelial B receptor was defined within a 10 A° radius with 
the centroid as CE atom of ASP81. The number of poses for each 
inhibitor was set 100, and early termination was allowed if the 
top three bound conformations of a ligand were within 1.5X 
RMSD [13]. After docking, the individual binding poses of each 
ligand were observed and their interactions with the protein 
were studied.  
 
 
Figure 1: Modeling of Endothelin B receptor with sequence 
aligned  (A) with 3C9M morphed (B) to build 3D model 
structure  (C) and the model structure Ramachandran’s plots 
(D) 
 
Results: 
Homology Modeling of Endothelin – B receptor Domain 
A high level of sequence identity should guarantee a more 
accurate alignment between the target sequence and template 
structure, and here 3C9M (Chain A, Structure of a mutant 
bovine Rhodopsin in hexagonal crystal form protein) with 
Endothelin-B receptor have high sequence identity and the 
identity of the reference protein with the Endothelin B receptor 
domain is 36%.  Structurally conserved regions (SCRs) for the 
model and the template were determined by multiple sequence 
alignment (A) superimposition of template and model structure 
(B), 3D structure of modeled protein (C) and Ramachandran’s 
plot (D) are illustrated in Figure 1. In this study, the model is 
made up of residues 118 - 386 because the active domain region 
was identified in between these residues by the SBASE server. 
Coordinates from the reference protein (3C9M) to the SCRs, 
structurally variable regions (SVRs), N-termini and C-termini 
were assigned to the target sequence based on the satisfaction of 
spatial restraints (C). 
  
Superimposition of 3C9M with Endothelin- B receptor domain 
This model was refined by molecular dynamics method and the 
final stable structure of the Endothelial B receptor is BIOINFORMATION  open access 
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superimposed with Cα trace of template. The weighted root 
mean square deviation of Cα trace between the template and 
final refined models was 1.81 Å. This final refined model was 
used for the identification of active site and for docking of the 
substrate with the protein. This protein has the structural 
alignment with 13 helices and 2 sheets like a covered barrel 
shape. The overall scores indicates acceptable protein 
environment. After the refinement process, validation of the 
model was carried out using Ramachandran plot calculations 
computed with the PROCHECK program. Altogether 86.7% of 
the residues of Endothelin B receptor were in  favored and 
allowed regions. The overall PROCHECK G-factor of 
Endothelin-B receptors was – 0.16 and VERIFY 3D environment 
profile was good. The compatibility score above zero in the 
VERIFY-3D program showed except ten, all residues are 
reasonable which makes us to believe that the structure of the 
Endothelin-B receptor protein is reliable.  
 
Active site Identification of Endothelin B receptor  
The possible binding sites of Endothelin B receptor was 
searched based on the structural comparison of template and 
the model build with CASTP server. Since, Endothelin B and 
the 3C9M are well conserved in both sequence and structure; 
their biological function should be identical. The predicted 
results are interesting and its shows the amino acid position 17-
22, 78-98 and 197-208 are predicted to conserved with the active 
site. Here we consider the experimental binding sites of 3C9M 
include some of the residues as mentioned above. Thus in this 
study ARG 82, ARG 84 and HIS 197 are chosen as the more 
favorable sites to dock the substrate. 
 
Docking of inhibitors within the active site of Endothelin B 
receptor 
In the presence of inhibitory results of Bosentan, new structural 
features and fictionalization requirements were proposed for 
the basic Bosentan scaffold that could increase affinity with 
Endothelin B receptor and consequently improves the anti 
hyper tense property [14]. Among these requirements, the 
modifications of the group in the structure by a more polar 
group were expected to increase the activity. These interesting 
results prompted us to prepare Bosentan analogues. Here we 
developed different analogues based on the structure of 
Bosentan by replacing with more polar groups than already 
existing groups, with little change in the properties of 
analogues represented in Table 1 (see supplementary 
material). These were used for docking studies to identify 
better drug derivative. Docking of inhibitors given in Table 1 
(see supplementary material) with Endothelin B was 
performed using GOLD 3.0.1, which is based on genetic 
algorithm (CCDC). The structure of Bosentan used for 
designing derivatives. The docking procedure includes several 
steps. First, the protein-ligand complex is generated using the 
GOLD package without constraints between the ligand and the 
specific amino acids of the pocket. The algorithm exhaustively 
searches the entire rotational and translational space of the 
ligand with respect to the receptors. The flexibility of the ligand 
is given by dihedral angle variations. The various solutions 
evaluated by a score, which is equivalent to the absolute value 
of the total energy of the ligand in the protein environment. 
Thus docking with the program GOLD version 3.0.1 was 
employed to locate the appropriate binding orientation and 
conformation of compounds with Endothelin B receptor.  
Gold Score fitness function: 
Gold Score performs a force field based scoring function and is 
made up of four components namely, hydrogen bond energy 
(H-bond); vander Waals energy (External vdW); vander Waals 
energy (internal vdW) and Intermolecular hydrogen bond 
(internal H-bond) energy. The external vdw score is multiplied 
by a factor of 1.375 when the total fitness score is computed. 
This is an empirical correction to encourage protein-ligand 
hydrophobic contact. The fitness function has been optimized 
for the prediction of ligand binding positions [15]. 
 
GoldScore Fitness = S (hb_ext) + 1.3750*S (vdw_ext) + S (hb_int) + 
1.0000*S (int) 
S (int) = S (vdw_int) + S (tors) 
 
Where S (hb_ext) is the protein-ligand hydrogen bond score, S 
(vdw_ext) is the protein-ligand van der Waals score, S (hb_int) 
is the score from intramolecular hydrogen bond in the ligand 
and S (vdw_int) is the score from intramolecular strain in the 
ligand. 
 
 
Figure 2:  Comparisons of interactions between Bosentan and 
its derivatives against Endothelin B receptor 
 
Among the 29 inhibitors BD6 derivate of Bosentan showed high 
affinity than others towards Endothelin B. The structure of the 
BD6 was shown in the Figure 2. Bosentan docked results shows 
interaction of Endothelin B receptor with 2 hydrogen bonds. 
The active residues in the Endothelin B receptor ARG84 binds 
to O4 of Bosentan with one hydrogen bond. The other hydrogen 
bond is formed between SER88 and O25 of Bosentan. BD6 
derivative forms four hydrogen bonds with Endothelin B 
receptor with the active residues. It is observed that BD6 
derivative was located at center of active site and is stabilized 
by hydrogen bonding interactions and these interactions are 
represented in Table 2. Bosentan total Gold Score fitness 
function is 30.03 Kcal/mol. This shows that Bosentan has good 
inhibitory activity on Endothelin B receptor. Gold Score fitness 
function of BD6: Total Gold Score fitness function is 45.21 
Kcal/mol. Here we have chosen Gold Fitness function than 
Chem score fitness function as Gold score fitness function is 
marginally better than ChemScore fitness function. Even 
though, some other compounds in this library are having better BIOINFORMATION  open access 
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scoring the BD6 shows better interactions and those interactions 
in Bosentan binding region Table 3 (see supplementary 
material). So, we have demonstrated that, among the 29 
derivatives designed the binding capacity is highest for BD6 and 
can be further used for further investigations.  
 
Conclusion: 
In this work, we have constructed a 3D model of Endothelin B 
receptor of Homosapiens, and obtained a refined model after 
energy minimization. The validation of protein structure 
through SAVS server and NAMD validates the protein is stable 
enough. The stable structure is further used for docking with 
Bosentan and its derivatives. Docking results indicate that 
conserved amino-acid residues in Endothelin B receptor play an 
important role in maintaining a functional conformation and 
are directly involved in donor substrate binding. The 
interaction between the domain and the inhibitors proposed in 
this study are useful for understanding the potential 
mechanism of domain and the inhibitor binding. The hydrogen 
bonds play important role for the structure and function of 
biological molecule in this study, and we found that ARG 82, 
ARG 84 and HIS 197 of Endothelin B are important for strong 
hydrogen bonding interaction with these inhibitors. To the best 
of our knowledge ARG 82, ARG 84 is conserved in the domain 
and may be important for structural integrity or maintaining 
the hydrophobicity of the inhibitor-binding pocket. Among 29 
derivatives used for docking, BD6  derivative showed best 
binding energy than other compounds. The total fitness 
function is high for BD6 when compared to other derivatives 
including Bosentan. According to our investigations from the 
docking results BD6 (C26H27N5O7S) can act as better Endothelin 
antagonist. Future investigation of other theoretical studies and 
experimental studies may confirm that BD6 as a potent 
inhibitor. 
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Supplementary material: 
 
Table 1: Library of Bosentan  
S.NO DRUG  Molecular 
formula 
Molecular 
weight 
Molar refractivity 
cm3 
Index of 
refraction 
Density 
g /cm3 
Polaris ability     10-
24 cm3                   
1 BOSTN  C27H29N5O6S  551.61  143.69 ± 0.4  1.607± 0.02  1.325± 0.06  56.96±0.5 
2 BD1 C 28H31N5O6S  565.64  148.33 ± 0.4  1.601±0.02  1.307±0.06  58.80±0.5 
3 BD2 C 28H31N5O6S 565.64  148.33±  0.4  1.601±0.02  1.307±0.06 58.80±0.5 
4 BD3 C 28H31N5O5S  549.64  146.79 ± 0.4  1.589±0.02  1.263±0.06  58.19±0.5 
5 BD4 C 28H31N5O6S  565.64  148.33 ± 0.4  1.601±0.02  1.301±0.06  58.80±0.5 
6 BD5 C 26H27N5O7S  553.58  140.60 ± 0.4  1.626±0.02  1.394±0.06  55.74±0.5 
7 BD6 C 26H27N5O7S 553.58  140.60±  0.4  1.626±0.02  1.394±0.06  55.74±0.5 
8 BD7 C 26H27N5O7S  553.58  140.60 ± 0.4  1.626±0.02  1.394±0.06  55.74±0.5 
9 BD8 C 26H27N5O7S  553.58  140.60 ± 0.4  1.626±0.02  1.394±0.06  55.74±0.5 
10 BD9 C 29H33N5O5S  563.55  151.42 ± 0.4  1.585±0.02   1.248±0.06 60.02±0.5 
11 BD10 C 26H27N5O7S  553.58  140.60 ± 0.4  1.626±0.02  1.394±0.06  55.74±0.5 
12 BD11 C 26H27N5O6S  537.58  139.03 ± 0.4  1.613 ±0.02  1.345±0.06  55.11±0.5 
13 BD12 C 26H27N5O6S 537.58  139.03±0.4  1.613 ±0.02  1.345 ±0.06  55.11±0.5 
14 BD13 C 27H29N5O5S 535.61  142.16±  0.4  1.594 ±0.02  1.279  
±0.06  
56.35 ±0.5 
15 BD14 C 28H30N5O5S 548.63       NA         NA         NA       NA 
16 BD15 C 27H28N5O6S  550.60       NA         NA         NA       NA 
17 BD16 C 30H34N5O6S 592.68       NA         NA         NA       NA 
18 BD17 C 30H34N5O6S  592.68       NA          NA         NA       NA 
19 BD18 C 31H36N5O5S 590.71       NA          NA         NA       NA 
20 BD19 C 30H34N5O6S  592.68       NA              NA         NA       NA 
21 BD20 C 28H30N5O7S  580.63       NA           NA          NA        NA 
22 BD21 C 28H30N5O7S 580.63       NA        NA          NA       NA 
23 BD22 C 28H31N5O7S  581.64  149.86 ± 0.4  1.613±0.02  1.352 ±0.06  59.41 ±0.5 
24 BD23 C 28H31N5O6S  565.64  148.33 ± 0.4  1.601±0.02  1.307 ±0.06  58.79 ±0.5 
25 BD24 C 28H31N5O6S  565.64  148.30 ± 0.4  1.601±0.02  1.308 ±0.06  58.79 ±0.5 
26 BD25 C 28H31N5O6S  565.64  148.30 ± 0.4  1.601±0.02  1.308 ±0.06  58.79 ±0.5 
27 BD26 C 29H33N5O5S  563.66  151.42 ± 0.4  1.585 ±0.02  1.585 ±0.02  60.02 ±0.5 
28 BD27 C 28H31N5O6S  565.64  148.12 ± 0.4  1.616 ±0.02  1.335 ±0.06  58.72 ±0.5 
29 BD28 C 28H31N5O7S  581.64  149.86 ± 0.4  1.613 ±0.02  1.352 ±0.06  59.41 ±0.5 
30 BD29 C 28H31N5O7S  581.64  149.86 ± 0.4  1.613 ±0.02  1.352 ±0.06  59.41 ±0.5 
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Table 2: Scoring difference between Bosentan and its derivatives against Endothelin B receptor  
Ligands  Gold score  Interacting sites  Bosentan 
atom 
Bond 
length(Å) 
Bond angles 
(Deg) 
Bosentan  30.03 Kcal/mol  ARG84 (HH1) 
SER 88  (HG) 
O4 
O25 
2.397 
1.798 
105.05 
89.62 
Bosentan D6  45.21 Kcal/mol  ARG82 (HHE) 
ARG82 (HE) 
ARG84 (HH2) 
GLN200 (O) 
N16 
N21 
O26 
H58 
2.120 
2.032 
2.396 
2.321 
91.48 
80.81 
82.38 
63.86 
 
Table 3: Fitness scoring parameters from GOLD docking with known and unknown compounds 
S.NO DRUG   S(hb_ext) S(vdW_ext) S(hb_int)  S(int)  Total Fitness 
1 BOSTN  2.51  37.90  0.00  -24.59  30.03 
2 BD1  2.33  36.69  0.00  -26.86  25.92 
3 BD2  2.87  33.58  0.00  -14.14  34.91 
4 BD3  2.49  37.27  0.00  -11.77  41.97 
5 BD4  2.19  40.20  0.00  -15.38  42.09 
6 BD5  2.92  40.55  0.00  -134.81  -76.13 
7 BD6  4.35  44.70  0.00  -20.60  45.21 
8 BD7  4.63  35.47  0.00  -15.87  37.54 
9 BD8  4.50  39.47  0.00  -15.04  43.73 
10 BD9 2.00  39.83  0.00  -32.29  24.47 
11 BD10  0.78  38.22  0.00  -24.47  28.87 
12 BD11  1.38  38.59  0.00  -13.16  41.29 
13 BD12  0.55  42.66  0.00  -14.99  44.21 
14 BD13  0.48  40.74  0.00  -13.06  43.43 
15 BD14  2.04  37.98  0.00  -18.60  35.66 
16 BD15  1.43  42.38  0.00  -21.09  38.61 
17 BD16  0.54  36.63  0.00  -24.93  25.98 
18 BD17  0.45  36.63  0.00  -24.42  26.40 
19 BD18  2.62  36.66  0.00  -32.76  20.26 
20 BD19  2.72  35.50  0.00  -28.27  23.25 
21 BD20  0.58  36.32  0.00  -31.81  18.71 
22 BD21  1.63  37.91  0.00  -26.21  27.55 
23 BD22  3.84  36.63  0.00  -30.18  24.02 
24 BD23  1.59  37.06  0.00  -21.68  30.86 
25 BD24  1.28  36.95  0.00  -34.15  17.94 
26 BD25  1.34  48.86  0.00  -37.25  20.27 
27 BD26  2.13  37.67  0.00  -31.81  22.11 
28 BD27  0.46  37.99  0.00  -31.68  21.02 
29 BD28  1.10  35.58  0.00  -16.93  33.10 
30 BD29  0.98  38.74  0.00  -27.93  26.32 
Where: S (hb_ext) = Protein-ligand hydrogen bond score; S (vdw_ext) = Protein-ligand van der Waals score; S (hb_int)  = Score 
from intramolecular hydrogen bond in the ligand; S (int) = Score from intramolecular strain in the ligand. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 